ProfileGDS5678 / 1444107_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 75% 75% 75% 78% 74% 76% 76% 75% 77% 76% 77% 78% 75% 75% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.9662975
GSM967853U87-EV human glioblastoma xenograft - Control 24.9307175
GSM967854U87-EV human glioblastoma xenograft - Control 34.925875
GSM967855U87-EV human glioblastoma xenograft - Control 45.4542578
GSM967856U87-EV human glioblastoma xenograft - Control 54.9107374
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.934876
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.9959476
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.9554975
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.2062677
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.1691176
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.1708977
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.3807478
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.0065875
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.9311575